Psychedelics – News and Features

A single low dose of esketamine – the active form of the anesthetic drug, ketamine – can reduce depressive episodes when given immediately after childbirth, a new study has found.

New research has shown how blocking the activity of the Tiam1 enzyme in certain spinal neurons could reduce morphine tolerance and prolong the usefulness of morphine for pain relief.

Researchers have identified multiple brain regions that are unique to regulating emotions. The study is among the first of its kind to separate activity relating to emotion generation from emotion regulation in the human brain.

The hype and promise around psychedelic drug trials have accelerated legislation to liberalize access to these compounds. In this article, we delve into the pivotal events in psychedelic science that researchers in the field predict will shape the year 2024.

New treatments for depression are needed that act rapidly and also have sustained effects. Ketamine could be the answer.

Join us as we explore how innovation, ethics and even aesthetics look set to influence the landscape of life science research, creating new possibilities for treating human diseases, feeding our growing population and nurturing the scientists of the future.

How, exactly, DMT alters brain function to produce positive effects observed in clinical trials is not yet clear, though a study from scientists at Imperial College London has shed some light.

A traditional African psychedelic drug reduced symptoms of veterans’ brain injury in a small clinical study published in Nature Medicine.

New research has identified the neuropsychological effects of rapid-acting antidepressants, like ketamine and psilocybin, that underpin their effectiveness.

A team of researchers have completed the largest genomic diversity study for the genus Psilocybe. Their genomic analysis of 52 Psilocybe specimens includes 39 species that have never been sequenced.